Search

 

MediaMedia

Paris, 21 january 2013

Lupus : peptide P140/LupuzorTM effectiveness confirmed

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France. The peptide, known as P140/LupuzorTM, is well tolerated by patients and leads to regression of the disease. Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive license to use the peptide. Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immunosuppressants. These results are published online in the Annals of the Rheumatic Diseases.

To download the press release  Lupus

References:

Zimmer R., Scherbarth H.R., Rillo O.L., Gomez-Reino J. and Muller S. Annals of Rheumatic Diseases (doi: 10.1136/annrheumdis-2012-202460)

Contact information:

CNRS Researcher l Sylviane Muller l T +33 3 88 41 70 22 l S.Muller@ibmc-cnrs.unistra.fr

ImmuPharma l Robert Zimmer l T +33 3 89 66 13 22 l robert.zimmer@immupharma.com

CNRS Press l Laetitia Louis l T +33 1 44 96 51 37 l laetitia.louis@cnrs-dir.fr


Top

Latest press releases

All disciplines

Back to homepageContactcredits